Press Release
24 November 2026 08:27:00 CET

Affibody Enters Collaboration with Minerva Imaging to Strengthen Radiopharmaceutical Manufacturing and Supply

Stockholm, Sweden, November 24, 2026. Affibody Medical AB (“Affibody”), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), today announced a collaboration with Minerva Imaging ApS (“Minerva Imaging”), an integrated CRO and CDMO specialized in targeted radionuclide therapies. Under the Master Clinical Supply Agreement, Minerva Imaging will provide radiolabeling and distribution services to support Affibody's clinical development programs.

The collaboration represents an important step in strengthening Affibody's manufacturing network, ensuring a reliable supply of radiolabeled molecules for clinical studies. Minerva Imaging provides a broad range of therapeutic and diagnostic radioisotopes, complemented by radiolabeling services and established distribution capabilities globally.

“Establishing robust manufacturing and supply logistics is a critical component of radiopharmaceutical development, and we have been impressed by Minerva Imaging’s expertise, capabilities and ambitions as a CDMO specializing in the field,” said David Bejker, CEO of Affibody. “This collaboration provides a solid foundation for the clinical supply of our novel Radioligand Therapies as we continue to advance our pipeline.”

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody’s lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.

The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody’s main shareholder, Patricia Industries, is a part of Investor AB.

Further information can be found at: www.affibody.com.

About Minerva Imaging

Minerva Imaging is an integrated radiopharmaceutical CRO/CDMO headquartered in Ølstykke, Denmark, providing end-to-end services spanning target validation, preclinical models, PET/SPECT/CT /MRI imaging, radiochemistry, dosimetry, GMP manufacturing, and clinical supply. Minerva supports global sponsors across a broad isotope portfolio including Cu-64, Zr-89, Lu-177, At-211, Pb-212, Ac-225, and Tb-161 with clients across Europe, North America, and Asia.

Disclaimer

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Affibody Contact

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Media Contact

Richard Hayhurst, 59° North Communications, +44 (0) 7711 8215727, richard.hayhurst@59north.bio

Attachments

Affibody Enters Collaboration with Minerva Imaging to Strengthen Radiopharmaceutical Manufacturing and Supply